Company intelligence / Profile preview

Shanxi Ruisheng Biotechnology

Ownership: Private
Development stage: Commercial

Overview

Shanxi Ruisheng Biotechnology is a Chinese biotechnology company engaged in pharmaceutical and medicine manufacturing. In August 2024, Haili Biologics announced plans to acquire a majority stake in the company for RMB 935 million. The transaction would make Shanxi Ruisheng Biotechnology a holding subsidiary of Haili Biologics[4]. There are no publicly disclosed clinical results or drug development programs.

Modalities: Small moleculeBiologic
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Shanxi Ruisheng Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanxi Ruisheng Biotechnology.

Explore the full profile